Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$10.24 USD

10.24
512,695

+0.26 (2.61%)

Updated Sep 11, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm

by Zacks Equity Research

The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.

PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension

by Zacks Equity Research

PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.

Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows

by Zacks Equity Research

The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.

QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

by Zacks Equity Research

QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

by Zacks Equity Research

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

Walgreens' (WBA) New Partnerships Aid, Retail Sales Dip

by Zacks Equity Research

Walgreens Boots' (WBA) response toward combatting the pandemic - conducting COVID-19 tests at various locations and actively participating in vaccinating residents and staff - is impressive.

Illumina (ILMN) Expands NIPT Offering With New Collaboration

by Zacks Equity Research

Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, '22 View Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both its segments.

Looking for a Growth Stock? Why It is Time to Focus on National Vision (EYE)

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider National Vision (EYE).

New Strong Buy Stocks for May 26th

by Zacks Equity Research

DFIN, EYE, PATK, CCOI, and LL have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2021

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down

by Zacks Equity Research

Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.

Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.

Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe

by Zacks Equity Research

Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).

CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.

Bruker's (BRKR) Research Tools Enable New insight on PACS

by Zacks Equity Research

Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.

Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips

by Zacks Equity Research

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.

Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable

by Zacks Equity Research

Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.

Medtronic (MDT) Reveals Promising Results From Evolut Trial

by Zacks Equity Research

The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.

LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation

by Zacks Equity Research

The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.

Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal

by Zacks Equity Research

Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.

EYE or SRDX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EYE vs. SRDX: Which Stock Is the Better Value Option?

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

by Zacks Equity Research

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.